Drug Profile
Research programme: monoterpene analogues - DOR BioPharma/University of Wisconsin-Madison
Latest Information Update: 07 Dec 2006
Price :
$50
*
At a glance
- Originator DOR BioPharma; University of Wisconsin-Madison
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Dec 2001 Endorex Corporation is now called DOR BioPharma
- 21 May 1999 Preclinical development for Cancer in USA (Unknown route)